Loading…
7Tabz Retail, LLC was warned for marketing unapproved new drugs containing 7-hydroxymitragynine (7-OH) in various dosage strengths through their website without FDA approval, violating sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act. The company made drug claims on their product pages including "Pain Relief," "Mood Boost," and "Recharge & Relax," establishing intended use as drugs. FDA expressed serious public health concerns because 7-OH is a potent mu-opioid agonist with opioid-like effects, the agency had received adverse event reports for the company's products, and the packaging/labeling could appeal to children.